Australia - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 4.16 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; iron oxide red; magnesium stearate; mannitol; croscarmellose sodium; aspartame; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 6000; iron oxide yellow; hypromellose; titanium dioxide; hyprolose; magnesium stearate; iron oxide red; lactose monohydrate; microcrystalline cellulose - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Israel - engelsk - Ministry of Health

novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - metformin hydrochloride 1000 mg; vildagliptin 50 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Israel - engelsk - Ministry of Health

novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - metformin hydrochloride 500 mg; vildagliptin 50 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Israel - engelsk - Ministry of Health

novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - vildagliptin 50 mg; metformin hydrochloride 850 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - letrozole -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - amlodipine besilate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amlodipine besilate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amlodipine besilate -

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - dermatophagoides farinae allergen extract 50 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 50 ir ((european house dust mite)); dermatophagoides farinae allergen extract 150 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 150 ir ((dermatophagoides pteronyssinus)) - sublingual tablet - 100ir & 300ir - active: dermatophagoides farinae allergen extract 50 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 50 ir ((european house dust mite)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose active: dermatophagoides farinae allergen extract 150 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 150 ir ((dermatophagoides pteronyssinus)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.